Physician profile
Michael Gross
NPI 1922663541
$5,096.46
in general payments reported to CMS, 2019-2025
15 companies · $2,475 in 2025
The $2,475 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $93.33 · 2023: $829 · 2024: $1,584 · 2025: $2,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Travel and Lodging: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.08 |
| Travel and Lodging | $1,275.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,704.03 | 2022-2025 | Ams 700, Advance Xp, Spaceoar Vue System - 10ml |
| Urogen Pharma, INC. | $610.37 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $277.90 | 2025 | |
| Olympus America INC. | $227.29 | 2024 | Itind System |
| Medtronic, INC. | $212.29 | 2023-2025 | Interstim, Signia |
| C. R. Bard, INC. & Subsidiaries | $149.23 | 2023 | |
| Photocure INC | $139.80 | 2025 | Cysview |
| Genzyme Corporation | $135.81 | 2023 | |
| Endo USA, INC. | $123.52 | 2025 | Xiaflex |
| Axonics, INC. | $117.30 | 2024 | Axonics |
| Baxter Healthcare | $114.53 | 2021 | |
| Tempus Ai, INC | $113.29 | 2024 | |
| Becton, Dickinson and Company | $98.40 | 2023 | Phasix Mesh |
| Astellas Pharma US INC | $42.83 | 2023 | Xtandi |
| Sumitomo Pharma America, INC. | $29.87 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.